- To determine if curcuminoids modulate cellular proliferation as measured by
proliferating cell nuclear antigen (PCNA) in the colorectal mucosa of subjects with
previously resected adenomatous colonic polyps.
Hypothesis: Curcuminoids decrease cellular proliferation in the colorectal mucosa of
subjects with previously resected sporadic adenomatous colonic polyps.
- To determine if curcuminoids modulate apoptosis, as measured by TUNEL assay, in the
colorectal mucosa of subjects with previously resected adenomatous colonic polyps.
Hypothesis: Curcuminoids increase apoptosis in colorectal mucosa of subjects with previously
resected sporadic adenomatous colonic polyps.
- To determine if curcuminoids modulate COX-2 expression as measured by
immunohistochemical assays in subjects with previously resected adenomatous colonic
Hypothesis: Curcuminoids decrease colorectal mucosa COX-2 expression in subjects with
previously resected sporadic adenomatous colonic polyps.
- To determine if curcuminoids modulate COX-2 activity as measured by urinary eicosanoids
Hypothesis: Curcuminoids decrease concentrations of urinary eicosanoids.
- A diagnosis for colon/rectal polyp resection, polypectomy
- Subjects must be able to have the capacity and must be willing to provide informed
- Premenopausal women must be surgically incapable of childbearing or be using a
medically acceptable method of contraception (oral contraceptives, diaphragms,
condoms with spermicide, IUD, progesterone injection or implant) throughout the
entire length of the study
- Men should wear condoms during the duration of the study given the unknown effects of
curcumin on sperm viability, fertility
- Previous or current history of colorectal cancer
- Previous history of Familial Polyposis Syndromes
- Previous history of inflammatory bowel disease
- Previous surgery of the large bowel
- Liver disease defined as AST and ALT>3x upper limit of normal
- Known history of gallstones, biliary colic or serum bilirubin >2.0
- Cardiac disease including myocardial infarction, congestive heart failure, arrhythmia
- Renal disease defined as creatinine >1.5
- Hematopoietic disease defined as WBC<4000, platelet count <100,000, hemoglobin<10.0
or coagulation or bleeding disorder
- Significantly impaired gastrointestinal function or absorption
- Peptic ulcer disease
- Active infection including viral, bacterial, atypical or fungal infections of any
organ system including HIV
- Previous history of allergy to turmeric, Indian curries, aspirin or NSAIDs
- Pregnant or lactating women
- Dementia or other neurologic or psychiatric disease which may impede the ability to
follow the protocol
- Inability to swallow pills
- Prior or concurrent therapy with any herbal or dietary supplement containing
- Concurrent use of anticoagulants or antiplatelets including warfarin, clopidogrel
- Prior or concurrent use of colorectal cancer chemopreventive agents including
herbals: Sulindac or other NSAIDs, aspirin, COX-2 inhibitors, 5-aminosalicylate,
folate, calcium, or their use within 14 days of enrollment
- Concurrent use of immunosuppressants